Paradoxiom Capital L.P. Invests $4.82 Million in Axon Enterprise, Inc. (NASDAQ:AXON)

Paradoxiom Capital L.P. bought a new position in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 8,109 shares of the biotechnology company's stock, valued at approximately $4,819,000.

Other large investors have also recently made changes to their positions in the company. New Wave Wealth Advisors LLC bought a new stake in shares of Axon Enterprise in the 4th quarter worth about $40,000. Y.D. More Investments Ltd bought a new stake in shares of Axon Enterprise in the 4th quarter worth about $45,000. Stonebridge Financial Group LLC purchased a new position in shares of Axon Enterprise during the 4th quarter worth about $53,000. GPS Wealth Strategies Group LLC boosted its stake in shares of Axon Enterprise by 74.1% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 40 shares during the period. Finally, Berbice Capital Management LLC purchased a new position in shares of Axon Enterprise during the 4th quarter worth about $59,000. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Stock Up 0.7%

Shares of NASDAQ:AXON traded up $4.79 during trading hours on Friday, hitting $733.18. The company's stock had a trading volume of 419,101 shares, compared to its average volume of 759,084. Axon Enterprise, Inc. has a 52 week low of $273.52 and a 52 week high of $735.68. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The company has a market capitalization of $57.08 billion, a price-to-earnings ratio of 189.45, a P/E/G ratio of 5.17 and a beta of 1.24. The firm's fifty day moving average price is $584.61 and its 200 day moving average price is $594.51.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. During the same quarter in the previous year, the business posted $1.15 EPS. The company's quarterly revenue was up 31.3% compared to the same quarter last year. As a group, research analysts expect that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Insider Buying and Selling

In other Axon Enterprise news, Director Jeri Williams sold 307 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total transaction of $169,685.04. Following the transaction, the director now owns 1,627 shares in the company, valued at approximately $899,275.44. This represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, President Joshua Isner sold 9,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $683.31, for a total transaction of $6,149,790.00. Following the transaction, the president now owns 308,714 shares in the company, valued at $210,947,363.34. The trade was a 2.83% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,764 shares of company stock worth $14,856,635 in the last 90 days. 4.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on AXON. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday. Barclays lifted their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. JMP Securities reaffirmed an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Northcoast Research cut shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. Finally, Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $652.73.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.